Coya Therapeutics, Inc. (COYA) income statement
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/3019% above fair value
$3.09+0.07 (+2.32%)
Close on Nov 18, 2026Market cap $72.48MP/E –Yield –
Coya Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -675.3%
- Net margin
- -643.5%
- Return on equity, FY2025
- -51.4%
Financial strength
- Current ratio
- 7.24
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 663.6%
Valuation
- P/E ratio
- –
- Price to sales
- 15.46
- Price to book
- 2.16
- Dividend yield
- –
See a number that looks wrong?